A review by The Recorder of SEC filings for 17 companies that had prominent Silicon Valley lawyers serving as directors has uncovered questionable option grant dates for executives at five. While the grant patterns aren't necessarily evidence of wrongdoing, they do suggest that suspect pay practices at startups may be more commonplace than previously thought. They also raise new questions about what some name-brand lawyers knew, or should have known, in their roles as directors.
August 28, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
For Amylin Pharmaceuticals Inc., 1998 was a rough year. Poor results in a series of clinical trials caused the company to lay off 80 percent of its workers. By Oct. 22, the company’s shares had fallen from $6.62 to a low of 31 cents.
The shares began to climb, though, as the company figured out what had gone wrong in the clinical trials.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
